文献速递血栓与止血

使用非凝血因子产品治疗伴抑制物血友病患者的新疗法

New therapies using nonfactor products for patients with hemophilia and inhibitors.
PubMed 文献 · Blood · 2018-12-17

综述非凝血因子产品(艾美赛珠单抗、fitusiran、concizumab)用于伴或不伴抑制物血友病患者预防治疗的现状。临床试验显示此类产品可显著减少出血事件,艾美赛珠单抗已在国际获批。但接受活化凝血酶原复合物重复输注的5例艾美赛珠单抗治疗患者发生血栓性微血管病和血栓栓塞,1例fitusiran治疗患者在接受FVIII产品重复输注后发生窦静脉血栓。监测止血功能的技术及更广泛经验仍需进一步评估。

要点

  • 非凝血因子产品预防治疗可显著减少伴或不伴抑制物血友病患者的出血事件。
  • 艾美赛珠单抗已在国际获批;fitusiran和concizumab的临床试验正在进行中。
  • 5例艾美赛珠单抗治疗患者在接受活化凝血酶原复合物重复输注后发生血栓性微血管病和血栓栓塞。

核心结论

  • 非凝血因子产品具有有前景的止血特性,但需在血友病中心积累更广泛经验以确立合适的治疗策略。

研究设计与样本

  • 综述,总结非凝血因子产品(艾美赛珠单抗、fitusiran、concizumab)的临床试验现状。

主要发现

  • 非凝血因子产品预防治疗支持伴或不伴抑制物血友病患者出血事件的显著减少。
  • 5例接受艾美赛珠单抗治疗并反复输注活化凝血酶原复合物的患者发生血栓性微血管病和血栓栓塞。
  • 1例接受fitusiran治疗并反复输注FVIII产品的患者发生窦静脉血栓。
  • 接受非凝血因子产品联合旁路制剂或FVIII/FIX治疗的患者,其止血功能的可靠监测技术需进一步评估。

关键数值与推荐

  • 艾美赛珠单抗已获国际批准使用。
  • fitusiran和concizumab的临床试验正在进行中。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 接受非凝血因子产品联合旁路制剂或FVIII/FIX治疗的患者,其止血功能的可靠监测技术需进一步评估。
  • 需在血友病中心积累更广泛经验以确立合适的治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Regular prophylaxis with factor VIII (FVIII) or FIX products to prevent bleeding in patients with severe hemophilia A (HA) and HB, respectively, results in marked suppression of the onset of arthropathy and contributes greatly to improvements in quality of life. Some issues remain with the use of clotting factor replacement therapy, however. The need for multiple IV infusions is associated with a substantial mental and physical burden, and the hemostatic effect of bypassing agents (BPAs) in patients with inhibitor is inconsistent. The development of subcutaneous products with prolonged hemostatic efficiency, irrespective of the presence of inhibitors, has been a longtime wish for patients. A new class of therapeutic agents that act by enhancing coagulation (emicizumab) and inhibiting anticoagulant pathways (fitusiran and concizumab) have been established, and clinical trials using these nonfactor products are ongoing. The current findings have demonstrated that prophylaxis by nonfactor products supports marked reductions of bleeding episodes in hemophilia patients with or without inhibitor. Emicizumab has already been approved for use internationally. Some concerns are evident, however. Thrombotic microangiopathy and thromboembolism have occurred in 5 emicizumab-treated patients receiving repeated infusions of activated prothrombin complex concentrates, and a sinus vein thrombosis has occurred in a fitusiran-treated patient receiving repeated infusions of FVIII product. Moreover, reliable techniques to monitor hemostatic function in patients receiving nonfactor products with concomitant BPA or FVIII/FIX therapies require further assessment. These novel therapeutic agents have promising hemostatic properties, although wider experience in hemophilia centers is warranted to establish appropriate therapeutic strategies.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Nogami K, Shima M. New therapies using nonfactor products for patients with hemophilia and inhibitors. Blood. 2018. PMID: 30559263. doi:10.1182/blood-2018-07-820712

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。